Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies
- PMID: 11524712
- DOI: 10.1086/321841
Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies
Abstract
Studies with fluoroquinolones have led to a general method for restricting the selection of antibiotic-resistant mutants. The strategy is based on the use of antibiotic concentrations that require cells to obtain 2 concurrent resistance mutations for growth. That concentration has been called the "mutant prevention concentration" (MPC) because no resistant colony is recovered even when >10(10) cells are plated. Resistant mutants are selected exclusively within a concentration range (mutant selection window) that extends from the point where growth inhibition begins, approximated by the minimal inhibitory concentration, up to the MPC. The dimensions of the mutant selection window can be reduced in a variety of ways, including adjustment of antibiotic structure and dosage regimens. The window can be closed to prevent mutant selection through combination therapy with > or =2 antimicrobial agents if their normalized pharmacokinetic profiles superimpose at concentrations that inhibit growth. Application of these principles could drastically restrict the selection of drug-resistant pathogens.
Similar articles
-
Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.Vet Microbiol. 2007 Jan 31;119(2-4):304-10. doi: 10.1016/j.vetmic.2006.08.018. Epub 2006 Aug 17. Vet Microbiol. 2007. PMID: 16987619
-
Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.J Infect Dis. 2002 Feb 15;185(4):561-5. doi: 10.1086/338571. Epub 2002 Jan 31. J Infect Dis. 2002. PMID: 11865411
-
Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations.J Infect Dis. 2000 Aug;182(2):517-25. doi: 10.1086/315708. Epub 2000 Jul 24. J Infect Dis. 2000. PMID: 10915083
-
The mutant selection window and antimicrobial resistance.J Antimicrob Chemother. 2003 Jul;52(1):11-7. doi: 10.1093/jac/dkg269. Epub 2003 Jun 12. J Antimicrob Chemother. 2003. PMID: 12805267 Review.
-
Mutant selection window hypothesis updated.Clin Infect Dis. 2007 Mar 1;44(5):681-8. doi: 10.1086/511642. Epub 2007 Jan 24. Clin Infect Dis. 2007. PMID: 17278059 Review.
Cited by
-
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.Antimicrob Agents Chemother. 2005 Sep;49(9):3966-9. doi: 10.1128/AAC.49.9.3966-3969.2005. Antimicrob Agents Chemother. 2005. PMID: 16127084 Free PMC article.
-
Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37.Int J Nanomedicine. 2019 Dec 10;14:9777-9792. doi: 10.2147/IJN.S230269. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31849468 Free PMC article.
-
Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.Antimicrob Agents Chemother. 2000 Sep;44(9):2581-4. doi: 10.1128/AAC.44.9.2581-2584.2000. Antimicrob Agents Chemother. 2000. PMID: 10952625 Free PMC article.
-
Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans.Antimicrob Agents Chemother. 2003 Oct;47(10):3099-103. doi: 10.1128/AAC.47.10.3099-3103.2003. Antimicrob Agents Chemother. 2003. PMID: 14506015 Free PMC article.
-
Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.Antimicrob Agents Chemother. 2004 Dec;48(12):4733-44. doi: 10.1128/AAC.48.12.4733-4744.2004. Antimicrob Agents Chemother. 2004. PMID: 15561851 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical